Stefanie Brackin, APRN
Family · Jonesboro, ARNPI 1225512635
Payments from drug & device makers
Across 530 payments — averaging $95.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$43K
- Novartis$778
- AstraZeneca$775
- EMD Serono, Inc.$738
- SK Life Science, Inc.$679
- Biogen$641
- plus $4K from 34 others
What the payments were for
- Speaking & faculty fees$40,53380%
- Travel & lodging$4871%
- Food & beverage$9,66119%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 147 | $43,245 |
| Novartis | 49 | $778 |
| AstraZeneca(2 entities) | 31 | $775 |
| EMD Serono, Inc. | 29 | $738 |
| SK Life Science, Inc. | 28 | $679 |
| Biogen | 32 | $641 |
| Amgen(2 entities) | 23 | $427 |
| MDD US Operations, LLC | 14 | $405 |
| Pfizer | 38 | $362 |
| Lundbeck LLC | 21 | $348 |
| Lilly USA, LLC | 13 | $200 |
| Amneal Pharmaceuticals LLC | 7 | $193 |
| Argenx US, Inc. | 9 | $179 |
| UCB, Inc. | 8 | $175 |
| Eisai Inc. | 8 | $171 |
| Teva Pharmaceuticals USA, Inc. | 9 | $164 |
| Neurelis, Inc. | 8 | $145 |
| Nevro Corp. | 4 | $144 |
| Neurocrine Biosciences, Inc. | 9 | $131 |
| Sumitomo Pharma America, Inc. | 4 | $90 |
| Otsuka America Pharmaceutical, Inc. | 3 | $81 |
| Avion Pharmaceuticals | 4 | $74 |
| Alnylam Pharmaceuticals Inc. | 4 | $65 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $52 |
| Impel Pharmaceuticals Inc. | 3 | $48 |
| Tanabe Pharma America, Inc. | 3 | $47 |
| Banner Life Sciences, LLC | 2 | $43 |
| Sanofi | 2 | $42 |
| Kyowa Kirin, Inc. | 2 | $39 |
| Genentech USA, Inc. | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $21 |
| Medtronic | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Bristol Myers Squibb | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Livanova USA, Inc. | 1 | $13 |
| Corium, LLC | 2 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,681 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 200 | $250,512 |
| Kesimpta PenOfatumumab | 15 | $153,254 |
| Aimovig AutoinjectorErenumab-Aooe | 159 | $142,507 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $95,034 |
| QuliptaAtogepant | 48 | $58,341 |
| Nurtec OdtRimegepant Sulfate | 44 | $48,538 |
| Emgality PenGalcanezumab-Gnlm | 59 | $46,115 |
| XcopriCenobamate | 30 | $33,595 |
| Emgality SyringeGalcanezumab-Gnlm | 26 | $31,479 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 23 | $16,551 |
| Teriflunomide | 18 | $13,328 |
| FycompaPerampanel | 16 | $13,084 |
| Gabapentin | 421 | $12,048 |
| Duloxetine Hcl | 254 | $5,779 |
| Pregabalin | 246 | $5,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $43,245 | $308,853248 claims |
| PfizerNurtec Odt | $362 | $48,53844 claims |
| SK Life Science, Inc.Xcopri | $679 | $33,59530 claims |
| Eisai Inc.Fycompa | $171 | $13,08416 claims |
| Upsher-smith Laboratories LLCTopiramate | $16 | $3,124204 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.
Other family in Jonesboro
- Jessica MatthewsJonesboro$19K
- Kimberly DanielsJonesboro$14K
- Kimberly RoddyJonesboro$12K
- Christopher JordanJonesboro$12K
- Amber ToombsJonesboro$12K
- Tracy ThompsonJonesboro$11K
- Ashley SheltonJonesboro$10K
- Steven VanderbiltJonesboro$10K
- Erika VanceJonesboro$10K
- Ashley DentonJonesboro$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.